Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Lattice-Based Radiotherapy and Chemoimmunotherapy Preceding Response-Adapted Definitive Chemoradiation for Non-Low Risk Oropharyngeal Squamous Cell Carcinoma
NCT07428148Phase 2Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, carboplatin, paclitaxel in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by NYU Langone Health. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07428148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428148.